Synonyms of Morquio Syndrome
- Morquio Disease
- MPS IV
- Mucopolysaccharidosis IV
- Morquio Syndrome A
- Morquio Syndrome B
Morquio syndrome (mucopolysaccharidosis type IV; MPS IV) is a mucopolysaccharide storage disease that exists in two forms (Morquio syndromes A and B) and occurs because of a deficiency of the enzymes N-acetyl-galactosamine-6-sulfatase and beta-galactosidase, respectively. A deficiency of either enzyme leads to the accumulation of mucopolysaccharides in the body, abnormal skeletal development, and additional symptoms. In most cases, individuals with Morquio syndrome have normal intelligence. The clinical features of MPS IV-B are usually fewer and milder than those associated with MPS IV-A. Symptoms may include growth retardation, a prominent lower face, an abnormally short neck, knees that are abnormally close together (knock knees or genu valgum), flat feet, abnormal sideways and front-to-back or side-to-side curvature of the spine (kyphoscoliosis), abnormal development of the growing ends of the long bones (epiphyses), and/or a prominent breast bone (pectus carinatum). Hearing loss, weakness of the legs, and/or additional abnormalities may also occur.
The mucopolysaccharidoses (MPS) are a group of inherited lysosomal storage disorders. Lysosomes function as the primary digestive units within cells. Enzymes within lysosomes break down or digest particular nutrients, such as certain carbohydrates and fats. In individuals with MPS disorders, deficiency or malfunction of specific lysosomal enzymes leads to an abnormal accumulation of certain complex carbohydrates (mucopolysaccharides or glycosaminoglycans) in the arteries, skeleton, eyes, joints, ears, skin, and/or teeth. These accumulations may also be found in the respiratory system, liver, spleen, central nervous system, blood, and bone marrow. This accumulation eventually causes progressive damage to cells, tissues, and various organ systems of the body. There are several different types and subtypes of mucopolysaccharidosis. These disorders, with one exception, are inherited as autosomal recessive traits.
Developmental abnormalities in Morquio syndrome are usually detected late in the first year of life or later and may include deformities of the chest (flaring of the lower ribs or abnormal prominence of the breastbone), loose joints, abnormally short neck, or joint deformities such as knock-knees. Affected children have a characteristic facial appearance that may include an enlarged head, broad mouth, prominent cheekbones, an unusually small nose, widely spaced and thinly enameled teeth, and widely separated eyes with subtle corneal clouding. The liver and spleen may be mildly enlarged. Children with Morquio syndrome show marked growth retardation from early in life. The elbows, wrists, hips, knees and other large joints are abnormally flexible, causing overall instability. Early development and intelligence are typically normal. High frequency hearing impairment is common.
Skeletal X-rays typically show marked flattening of the vertebra. The long bones of the arms and legs are characteristically shorter and thicker than normal. The skull is large for the rest of the body. The connection between the first and second vertebrae in the neck is poorly developed and this abnormality can be life threatening. A trivial injury may cause the two vertebrae to slip on each other and compress the spinal cord. Surgery to stabilize the upper cervical spine, usually by spinal fusion, can be lifesaving but life expectancy is decreased somewhat despite surgery. The deformity of the chest causes a strain on the heart and lungs, which may eventually cause respiratory failure.
Morquio syndrome is an autosomal recessive genetic disorder in which a deficiency of lysosomal N-acetylgalactosamine-6-sulfatase in type A of the disorder, and a deficiency of lysosomal beta-galactosidase in type B, leads to an accumulation of keratan sulfate in the cells and tissues of the body. The two types never occur together in the same family.
Genetic diseases are determined by the combination of genes for a particular trait that are on the chromosomes received from the father and the mother.
Recessive genetic disorders occur when an individual inherits the same abnormal gene for the same trait from each parent. If an individual receives one normal gene and one gene for the disease, the person will be a carrier for the disease, but usually will not show symptoms. The risk for two carrier parents to both pass the defective gene and, therefore, have an affected child is 25% with each pregnancy. The risk to have a child who is a carrier like the parents is 50% with each pregnancy. The chance for a child to receive normal genes from both parents and be genetically normal for that particular trait is 25%. The risk is the same for males and females.
Morquio syndrome affects males and females equally often. Estimates of birth prevalence range from 1/40,000 to 1/200,000 births. Morquio syndrome type A occurs more often than type B.
As a group, lysosomal storage diseases (of which the mucopolysaccharidoses are a subgroup) are believed to have an estimated frequency of about one in every 5,000 live births. Although the individual diseases are rare, the group together affects many people around the world.
There are many types of mucopolysaccharide (MPS) storage diseases. Information about each type of MPS storage disease can be located in the Rare Disease Database. (For more information, choose "MPS Disorders" as your search term in the Rare Disease Database.)
The mucolipidoses are a family of similar disorders, producing symptoms very much like those of the mucopolysaccharidoses.
I-cell disease, or mucolipidosis type II, resembles Hurler syndrome and the two disorders are very difficult to distinguish. I-cell disease has similar physical and mental deterioration as MPS I, but usually occurs earlier and is more severe. I-cell disease is characterized by diffused deficiency of lysosomal enzymes with the cell and is not associated with excretion of mucopolysaccharides in the urine.
Pseudo-Hurler polydystrophy (mucolipidosis type III) is also transmitted by autosomal inheritance, but it is characterized by a deficiency of multiple lysosomal enzymes needed to break down mucopolysaccharides. ML III affects males more often than females, and can be identified by such symptoms as claw-like hands, somewhat coarse facial features, dwarfism and pain in the hands. Intelligence tends to be normal in most patients, but mild mental retardation is sometimes present.
Ganglioside sialidase deficiency (mucolipidosis type IV) is a disorder of unknown cause characterized by early clouding of the cornea, mild to moderate mental retardation and enlargement of spleen and liver.
(For more information on the mucolipidoses, choose "ML Disorder" as your search term in the Rare Disease Database.)
Excessive amounts of keratan sulfate in the urine will usually be present. The diagnosis is confirmed with the finding of a deficiency of N-acetylgalactosamine-6-sulfatase (type A) or beta-galactosidase (type B) in blood or skin cells. Prenatal diagnosis of Morquio syndrome is possible through amniocentesis or sampling of tissue from the placenta (chorionic villus sampling).
The treatment of Morquio syndrome is symptomatic and supportive. Surgery to decompress and fuse the bones of the upper neck to the base of the skull can prevent destabilization of the cervical vertebrae and potential damage to the spinal cord.
Genetic counseling may be of benefit for affected individuals and their families.
Information on current clinical trials is posted on the Internet at www.clinicaltrials.gov. All studies receiving U.S. government funding, and some supported by private industry, are posted on this government web site.
For information about clinical trials being conducted at the NIH Clinical Center in Bethesda, MD, contact the NIH Patient Recruitment Office:
Tollfree: (800) 411-1222
TTY: (866) 411-1010
For information about clinical trials sponsored by private sources, contact:
Morquio Syndrome Resources
NORD Member Organizations:
(To become a member of NORD, an organization must meet established criteria and be approved by the NORD Board of Directors. If you're interested in becoming a member, please contact Susan Olivo, Membership Manager, at email@example.com.)
Clarke JTR. MPS-IV (Morquio Disease). In: The NORD Guide to Rare Disorders, Philadelphia: Lippincott, Williams and Wilkins, 2003:480.
Beighton P, McKusick VA. Heritable Disorders of Connective Tissue, 5th ed. St. Louis: CV Mosby, 1993.
Tomatsu S, et al. Mucopolysaccharidoses IVA (Morquio A): identification of novel common mutations in the N-acetylgalactosamine-6-sulfate sulfatase (GALNS) gene in Italians patients. Hum Mutat. 2004;24:187-8.
Walker PP, Rose E, Williams JG. Upper airways abnormalities and tracheal problems in Morquio's disease. Thorax. 2003;58:458-9.
Kjellen L, Lindahl V. The proteoglycans structures and functions. Ann Rev Biochem 1991;60:443-475.
FROM THE INTERNET
McKusick VA, ed. Online Mendelian Inheritance in Man (OMIM). Baltimore, MD: The Johns Hopkins University; Entry No. 253000; Last Update: 2/28/03, Entry No. 253010: Last Update: 5/1/02.
The information in NORD’s Rare Disease Database is for educational purposes only. It should never be used for diagnostic or treatment purposes. If you have questions regarding a medical condition, always seek the advice of your physician or other qualified health professional. NORD’s reports provide a brief overview of rare diseases. For more specific information, we encourage you to contact your personal physician or the agencies listed as “Resources” on this report.
The National Organization for Rare Disorders (NORD) web site, its databases, and the contents thereof are copyrighted by NORD. No part of the NORD web site, databases, or the contents may be copied in any way, including but not limited to the following: electronically downloading, storing in a retrieval system, or redistributing for any commercial purposes without the express written permission of NORD. Permission is hereby granted to print one hard copy of the information on an individual disease for your personal use, provided that such content is in no way modified, and the credit for the source (NORD) and NORD’s copyright notice are included on the printed copy. Any other electronic reproduction or other printed versions is strictly prohibited.
Copyright ©1986, 1987, 1988, 1990, 1995, 2003, 2005
Report last updated: 2008/03/31 00:00:00 GMT+0
NORD's Rare Disease Information Database is copyrighted and may not be published without the written consent of NORD.